Today, Dr. Benjamin Bakall, MD, PhD presented a late breaking abstract titled, “One Year Follow-up in a Phase 1/2 Clinical Trial of a Gene Modifier Therapy (OCU400) for the Treatment of Retinitis Pigmentosa” during the ASRS Annual meeting in Stockholm, Sweden.